✦ LIBER ✦

Anaesthesia for liver transplantation-a model for the anaesthetic management of end-stage hepatic failure

✍ Scribed by Peter M. Waterman

Book ID: 105686073
Publisher: Springer-Verlag
Year: 1983
Tongue: French
Weight: 321 KB
Volume: 30
Category: Article
ISSN: 1496-8975
DOI: 10.1007/bf03009976

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival after liver transplantation for

Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre–model for end-stage liver disease eras and the independent impact of hepatitis C virus

✍ Paul J. Thuluvath; Anurag Maheshwari; Nimisha P. Thuluvath; Geoffrey C. Nguyen; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 1 views

It has been suggested that hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC) may have worse outcomes after liver transplantation (LT) because of more aggressive tumor biology. In this study, we determined the post-LT survival of HCC patients with and without HCV using United Netwo

Renal outcomes after liver transplantati

Renal outcomes after liver transplantation in the model for end-stage liver disease era

✍ Pratima Sharma; Kathy Welch; Richard Eikstadt; Jorge A. Marrero; Robert J. Fonta 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

The proportion of patients undergoing liver transplantation (LT) with renal insufficiency has significantly increased in the Model for End-Stage Liver Disease (MELD) era. This study was designed to determine the incidence and predictors of post-LT chronic renal failure (CRF) and its effect on patien

Use of model for end-stage liver disease

Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature

✍ Cary Caldwell; Norman Werdiger; Sofia Jakab; Michael Schilsky; Antonios Arvelaki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Hepatic myelopathy (HM) is a rarely reported disorder characterized by progressive spastic paraparesis due to impaired corticospinal tract function in the setting of cirrhosis or portosystemic shunting. HM has not to date been recognized as a Model for End-Stage Liver Disease (MELD) exception for tr

Liver transplantation cost in the model

Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission

✍ Paula Buchanan; Nino Dzebisashvili; Krista L. Lentine; David A. Axelrod; Mark A. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

We examined the relationship between the total cost incurred by liver transplantation (LT) recipients and their Model for End-Stage Liver Disease (MELD) score at the time of transplant. We used a novel database linking billing claims from a large private payer with the Organ Procurement and Transpla

A systematic review of the performance o

A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation

✍ Evangelos Cholongitas; Laura Marelli; Vibhakorn Shusang; Marco Senzolo; Keith Ro 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 1 views

The Model for End-Stage Liver Disease (MELD) score is now used for allocation in liver transplantation (LT) waiting lists, replacing the Child-Turcotte-Pugh (CTP) score. However, there is debate as whether it is superior to CTP score to predict mortality in patients with cirrhosis on the LT waiting

A new priority policy for patients with

A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system

✍ Fabio Piscaglia; Valeria Camaggi; Matteo Ravaioli; Gian Luca Grazi; Matteo Zanel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 1 views

The best prioritization of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation under the model for end-stage liver disease (MELD) allocation system is still being debated. We analyzed the impact of a MELD adjustment for HCC, which consisted of the addition of an extra scor